Cargando…

AQP4‐IgG positive paraneoplastic NMOSD: A case report and review

INTRODUCTION: Neuromyelitis optica spectrum disorder (NMOSD; also known as Devic syndrome) is a clinical syndrome of central nervous system characterized by immune mediated attacks of acute optic neuritis and myelitis. Paraneoplastic neurological syndrome is a group of nervous system disorders resul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ding, Manqiu, Lang, Yue, Cui, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8553315/ https://www.ncbi.nlm.nih.gov/pubmed/34520629 http://dx.doi.org/10.1002/brb3.2282

Ejemplares similares

A case report on recurrent area postrema syndrome in AQP4-IgG-positive NMOSD
por: Shrestha, Ramesh, et al.
Publicado: (2022)

Area postrema syndrome: Frequency, criteria, and severity in AQP4-IgG–positive NMOSD
por: Shosha, Eslam, et al.
Publicado: (2018)

Different clinical phenotypes of AQP4-IgG positive NMOSD in two first degree relatives
por: Ssemmanda, Salvatore, et al.
Publicado: (2023)

Longitudinal Evaluation of Serum MOG-IgG and AQP4-IgG Antibodies in NMOSD by a Semiquantitative Ratiometric Method
por: Bollo, Luca, et al.
Publicado: (2021)

An Abnormally High Neutrophil-to-Lymphocyte Ratio Is Not an Independent Outcome Predictor in AQP4-IgG-Positive NMOSD
por: Carnero Contentti, Edgar, et al.
Publicado: (2021)

AQP4-IgG NMOSD, MOGAD, and double-seronegative NMOSD: is it possible to depict the antibody subtype using magnetic resonance imaging?
por: Fragoso, Diego Cardoso, et al.
Publicado: (2023)

Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD
por: Dinoto, Alessandro, et al.
Publicado: (2022)

Clinical utility of AQP4-IgG titers and measures of complement-mediated cell killing in NMOSD
por: Jitprapaikulsan, Jiraporn, et al.
Publicado: (2020)

International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab
por: Paul, Friedemann, et al.
Publicado: (2023)

Paraneoplastic NMOSD associated with EG junction adenocarcinoma expressing unprotected AQP4
por: Sudo, Atsushi, et al.
Publicado: (2018)

Myelitis features and outcomes in CNS demyelinating disorders: Comparison between multiple sclerosis, MOGAD, and AQP4-IgG-positive NMOSD
por: Fadda, Giulia, et al.
Publicado: (2022)

Peripapillary hyper-reflective ovoid mass-like structures (PHOMS) in AQP4-IgG-positive neuromyelitis optica spectrum disease (NMOSD) and MOG-IgG-associated disease (MOGAD)
por: Gernert, Jonathan A., et al.
Publicado: (2022)

Impaired response of blood neutrophils to cell-death stimulus differentiates AQP4-IgG-seropositive NMOSD from MOGAD
por: Schroeder-Castagno, Maria, et al.
Publicado: (2022)

Elevated serum levels of bone morphogenetic protein-9 are associated with better outcome in AQP4-IgG seropositive NMOSD
por: Masuda, Hiroki, et al.
Publicado: (2023)

Pain in AQP4-IgG-positive and MOG-IgG-positive neuromyelitis optica spectrum disorders
por: Asseyer, Susanna, et al.
Publicado: (2018)

Rapid Administration of High-Dose Intravenous Methylprednisolone Improves Visual Outcomes After Optic Neuritis in Patients With AQP4-IgG-Positive NMOSD
por: Akaishi, Tetsuya, et al.
Publicado: (2020)

Long‐Term Safety and Efficacy of Eculizumab in Aquaporin‐4 IgG‐Positive NMOSD
por: Wingerchuk, Dean M., et al.
Publicado: (2021)

Dynamic Changes in AQP4-IgG Level and Immunological Markers During Protein-A Immunoadsorption Therapy for NMOSD: A Case Report and Literature Review
por: Chen, Bo, et al.
Publicado: (2021)

CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications
por: Kaneko, Kimihiko, et al.
Publicado: (2018)

Paraneoplastic AQP4-IgG–Seropositive Neuromyelitis Optica Spectrum Disorder Associated With Teratoma: A Case Report and Literature Review
por: Ikeguchi, Ryotaro, et al.
Publicado: (2021)

Correction: CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications
Publicado: (2019)

Anti-AQP4–IgG-positive Leigh syndrome: A case report and review of the literature
por: Chen, Jun, et al.
Publicado: (2023)

NMOSD IgG Impact Retinal Cells in Murine Retinal Explants
por: Wolf, Hannah Nora, et al.
Publicado: (2023)

HLA association in MOG-IgG– and AQP4-IgG–related disorders of the CNS in the Dutch population
por: Bruijstens, Arlette L., et al.
Publicado: (2020)

Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders
por: Palace, Jacqueline, et al.
Publicado: (2019)

MOG-IgG- versus AQP4-IgG-Positive Optic Neuritis in Thailand: Clinical Characteristics and Long-Term Visual Outcomes Comparison
por: Narongkhananukul, Chanomporn, et al.
Publicado: (2020)

Comparative study of AQP4-NMOSD, MOGAD and seronegative NMOSD: a single-center Belgian cohort
por: Dauby, Solène, et al.
Publicado: (2021)

Clinical utility of testing AQP4-IgG in CSF: Guidance for physicians
por: Majed, Masoud, et al.
Publicado: (2016)

Helicobacter pylori infection may influence prevalence and disease course in myelin oligodendrocyte glycoprotein antibody associated disorder (MOGAD) similar to MS but not AQP4-IgG associated NMOSD
por: Malli, Chaithra, et al.
Publicado: (2023)

Higher longitudinal brain white matter atrophy rate in aquaporin-4 IgG-positive NMOSD compared with healthy controls
por: Masuda, Hiroki, et al.
Publicado: (2023)

An elderly female case of AQP4 and GFAP double-positive NMOSD coexisting with ovarian teratoma
por: Yang, Jiahui, et al.
Publicado: (2023)

Microstructural visual system changes in AQP4-antibody–seropositive NMOSD
por: Oertel, Frederike C., et al.
Publicado: (2017)

The effect of smoking on MRI lesion resolution in NMOSD-AQP4 and MOGAD
por: Berhanu, David, et al.
Publicado: (2023)

What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients
por: Hamid, Shahd H. M., et al.
Publicado: (2017)

Altered fovea in AQP4-IgG–seropositive neuromyelitis optica spectrum disorders
por: Motamedi, Seyedamirhosein, et al.
Publicado: (2020)

Cytoprotective IgG antibodies in sera from a subset of patients with AQP4-IgG seropositive neuromyelitis optica spectrum disorder
por: Tradtrantip, Lukmanee, et al.
Publicado: (2021)

Difference in the Source of Anti-AQP4-IgG and Anti-MOG-IgG Antibodies in CSF in Patients With Neuromyelitis Optica Spectrum Disorder
por: Akaishi, Tetsuya, et al.
Publicado: (2021)

The aquaporin4-IgG status and how it affects the clinical features and treatment response in NMOSD patients in Egypt
por: Kishk, Nirmeen A., et al.
Publicado: (2021)

Spontaneous remission lasting more than a decade in untreated AQP4 antibody–positive NMOSD
por: Pandit, Lekha, et al.
Publicado: (2017)

Reflections from a NMOSD case with serum AQP4-Ab negativity but CSF positivity: narrative review of how to interpret AQP4-Ab test results
por: Xue, Qun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hvg4hh7jqlkbgaf1bad58hhmeg